| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On November 2, 2004
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1976N-0052N
|
| OTC Nasal Decongestants
|
|
|
|
|
| 1999P-1340
|
| Declared Eternity eau de Parfum Misbranded
|
|
|
|
|
| 2000N-1571
|
| Enrofloxacin for Poultry: Opportunity for Hearing
|
|
|
|
|
| 2001P-0075
|
| Switch Status of Emergency Contraceptives from Rx to OTC
|
|
|
|
|
| 2002E-0340
|
| Antagon, U.S. Patent No. 4,801,577
|
|
|
|
|
| 2003P-0479
|
| Allow importation of Canadian versions of drugs that are approved to the United States
|
|
|
|
|
| 2004D-0193
|
| Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)
|
|
|
|
|
| 2004N-0289
|
| Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter
|
|
|
|
|
| 2004P-0386
|
| Reject New Drug Application 21-695
|
|
|
|
|
| 2004P-0485
|
| require the source of the dietary ingredient lycopene to be identified as from tomato,fungus, or synthetic
|
|
|
|
|
| 1976N-0052N
|
| OTC Nasal Decongestants
|
|
|
|
|
| NPR
3
|
| FDA
|
| Vol #:
|
| 77
|
|
|
|
|
| 1999P-1340
|
| Declared Eternity eau de Parfum Misbranded
|
|
|
|
|
| EMC 558
|
| L. Litwin
|
| Vol #:
|
| 24
|
|
|
|
|
| 2000N-1571
|
| Enrofloxacin for Poultry: Opportunity for Hearing
|
|
|
|
|
| EXB 666
|
| Bayer Corporation
|
| Vol #:
|
| 459
|
|
|
|
|
| EXB 667
|
| Bayer Corporation
|
| Vol #:
|
| 459
|
|
|
|
|
| EXB 668
|
| Bayer Corporation
|
| Vol #:
|
| 459
|
|
|
|
|
| EXB 669
|
| Bayer Corporation
|
| Vol #:
|
| 459
|
|
|
|
|
| 2001P-0075
|
| Switch Status of Emergency Contraceptives from Rx to OTC
|
|
|
|
|
| EMC 10978
|
| E. Edenfield
|
| Vol #:
|
| 296
|
|
|
|
|
| EMC 10979
|
| A. Irick
|
| Vol #:
|
| 296
|
|
|
|
|
| EMC 10980
|
| B. Crawford, PhD
|
| Vol #:
|
| 296
|
|
|
|
|
| EMC 10981
|
| O. Morderer
|
| Vol #:
|
| 296
|
|
|
|
|
| 2002E-0340
|
| Antagon, U.S. Patent No. 4,801,577
|
|
|
|
|
| N
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2003P-0479
|
| Allow importation of Canadian versions of drugs that are approved to the United States
|
|
|
|
|
| C 27
|
| R. Mullin
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004D-0193
|
| Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)
|
|
|
|
|
| EMC 291
|
| M. Alper, MD
|
| Vol #:
|
| 5
|
|
|
|
|
| 2004N-0289
|
| Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter
|
|
